DWT
CHRS icon

Dorsey & Whitney Trust’s Coherus Oncology CHRS Stock Holding History

Dorsey & Whitney Trust’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,410
Closed -$38.9K – 613
2023
Q3 		$38.9K Buy
+10,410
New +$48.1K ﹤0.01% 580

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dorsey & Whitney Trust's CHRS Position: Q4 2023 in Review

Dorsey & Whitney Trust sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 10,410 shares — an estimated $38.9K sold.

Dorsey & Whitney Trust first reported a position in CHRS in Q3 2023 and held it in 1 quarter. The position peaked at $38.9K in Q3 2023. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Dorsey & Whitney Trust reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Dorsey & Whitney Trust sold 10,410 Coherus Oncology shares in Q4 2023, an estimated $38.9K.
  • Dorsey & Whitney Trust first reported a position in Coherus Oncology in Q3 2023 and held it in 1 quarter.
  • Dorsey & Whitney Trust's Coherus Oncology position peaked at $38.9K in Q3 2023.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Dorsey & Whitney Trust's 13F filing for Q4 2023, filed 12 Feb 2024.